Paxlovid Not on China’s Reimbursement List
As the nation phases out its zero-COVID strategy following major protests, China’s National Healthcare Security Administration has left Pfizer’s Paxlovid off its reimbursement list. This comes as cases spike in the nation, with many patients purchasing the drug off the internet through India. However, other COVID drugs did make the cut.
Biotech Predicts Reduced COVID Sales and Signals Potential M&As
Despite tripling their sales last quarter, BioNTech’s CFO Jens Holstein signaled to investors that mergers and collaborations may be in [...]
Advertisement
